These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38652922)

  • 1. A non-midline unclassified glioneuronal tumor with H3K27M mutation enlarging the spectrum of CNS tumors H3K27ME3-altered.
    Aboubakr O; Senova S; Kauv P; Castel D; Ajlil Y; Saffroy R; Appay R; Métais A; Hasty L; Varlet P; Tauziède-Espariat A
    J Neuropathol Exp Neurol; 2024 Aug; 83(8):701-705. PubMed ID: 38652922
    [No Abstract]   [Full Text] [Related]  

  • 2. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
    Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
    Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations in the integrated diagnosis of pediatric glial and glioneuronal tumors: A single center experience.
    Colli SL; Cardoso N; Massone CA; Cores M; García Lombardi M; De Matteo EN; Lorenzetti MA; Preciado MV
    PLoS One; 2022; 17(4):e0266466. PubMed ID: 35363819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
    Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
    Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
    Damodharan S; Helgager J; Puccetti D
    Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
    Wang Q; Niu W; Pan H
    Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 10. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
    Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
    Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review.
    Onishi S; Ohba S; Kuraoka K; Kurashige T; Sugiyama K; Yamasaki F
    Neurocirugia (Astur : Engl Ed); 2022; 33(6):356-360. PubMed ID: 36333093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of rosette-forming glioneuronal tumors.
    Liu J; Lin F; Sun Y; Liu X
    Diagn Pathol; 2024 Feb; 19(1):39. PubMed ID: 38388383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
    Zhao H; Fang X; Xue B
    Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
    Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
    Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours.
    Appay R; Bielle F; Sievers P; Barets D; Fina F; Boutonnat J; Adam C; Gauchotte G; Godfraind C; Lhermitte B; Maurage CA; Meyronet D; Mokhtari K; Rousseau A; Tauziède-Espariat A; Tortel MC; Uro-Coste E; Burel-Vandenbos F; Chotard G; Pesce F; Varlet P; Colin C; Figarella-Branger D
    Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12813. PubMed ID: 35293634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.